|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2009-10-28
|
|
pubmed:abstractText |
Pemetrexed is a standard treatment against recurrent non-small cell lung cancer (NSCLC), and cetuximab has single-agent activity against NSCLC. This study evaluates the safety and efficacy of the combination of these agents in patients with advanced NSCLC.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1556-1380
|
|
pubmed:author |
pubmed-author:AnsariRafatR,
pubmed-author:BottemaBrianB,
pubmed-author:ClarkRomneeR,
pubmed-author:EdelmanMartin JMJ,
pubmed-author:HannaNasserN,
pubmed-author:JalalShadiaS,
pubmed-author:KoneruKarunaK,
pubmed-author:NattamSreenivasaS,
pubmed-author:RichardsArthurA,
pubmed-author:WaterhouseDavidD,
pubmed-author:WhiteAngelaA,
pubmed-author:WuJingweiJ,
pubmed-author:YuMenggangM
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
4
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1420-4
|
|
pubmed:meshHeading |
pubmed-meshheading:19701110-Adult,
pubmed-meshheading:19701110-Aged,
pubmed-meshheading:19701110-Aged, 80 and over,
pubmed-meshheading:19701110-Antibodies, Monoclonal,
pubmed-meshheading:19701110-Antineoplastic Agents,
pubmed-meshheading:19701110-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:19701110-Dose-Response Relationship, Drug,
pubmed-meshheading:19701110-Drug Therapy, Combination,
pubmed-meshheading:19701110-Female,
pubmed-meshheading:19701110-Follow-Up Studies,
pubmed-meshheading:19701110-Glutamates,
pubmed-meshheading:19701110-Guanine,
pubmed-meshheading:19701110-Humans,
pubmed-meshheading:19701110-Injections, Intravenous,
pubmed-meshheading:19701110-Lung Neoplasms,
pubmed-meshheading:19701110-Male,
pubmed-meshheading:19701110-Middle Aged,
pubmed-meshheading:19701110-Neoplasm Recurrence, Local,
pubmed-meshheading:19701110-Neoplasm Staging,
pubmed-meshheading:19701110-Receptor, Epidermal Growth Factor,
pubmed-meshheading:19701110-Retrospective Studies,
pubmed-meshheading:19701110-Survival Rate,
pubmed-meshheading:19701110-Thymidylate Synthase,
pubmed-meshheading:19701110-Treatment Outcome,
pubmed-meshheading:19701110-United States
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Pemetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): a phase I/II study from the Hoosier Oncology Group.
|
|
pubmed:affiliation |
Indiana University Simon Cancer Center, Indianapolis, Indiana 46202, USA. sjalal@iupui.edu
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
